Overexpression of GAS7 was shown to reverse this resistance, both in vitro and in vivo, suggesting that targeting the miR-4516/GAS7 axis could be a potential therapeutic strategy to overcome CIS resistance in OC [190]. The gene discussed is GAS7; the disease is in situ carcinoma.